Cargando…

How much leeway is there to relax COVID-19 control measures?

Following successful non-pharmaceutical interventions (NPI) aiming to control COVID-19, many jurisdictions reopened their economies and borders. As little immunity had developed in most populations, re-establishing higher contact carried substantial risks, and therefore many locations began to see r...

Descripción completa

Detalles Bibliográficos
Autores principales: Anderson, Sean C., Mulberry, Nicola, Edwards, Andrew M., Stockdale, Jessica E., Iyaniwura, Sarafa A., Falcao, Rebeca C., Otterstatter, Michael C., Janjua, Naveed Z., Coombs, Daniel, Colijn, Caroline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970422/
https://www.ncbi.nlm.nih.gov/pubmed/33971429
http://dx.doi.org/10.1016/j.epidem.2021.100453
_version_ 1783666424862998528
author Anderson, Sean C.
Mulberry, Nicola
Edwards, Andrew M.
Stockdale, Jessica E.
Iyaniwura, Sarafa A.
Falcao, Rebeca C.
Otterstatter, Michael C.
Janjua, Naveed Z.
Coombs, Daniel
Colijn, Caroline
author_facet Anderson, Sean C.
Mulberry, Nicola
Edwards, Andrew M.
Stockdale, Jessica E.
Iyaniwura, Sarafa A.
Falcao, Rebeca C.
Otterstatter, Michael C.
Janjua, Naveed Z.
Coombs, Daniel
Colijn, Caroline
author_sort Anderson, Sean C.
collection PubMed
description Following successful non-pharmaceutical interventions (NPI) aiming to control COVID-19, many jurisdictions reopened their economies and borders. As little immunity had developed in most populations, re-establishing higher contact carried substantial risks, and therefore many locations began to see resurgence in COVID-19 cases. We present a Bayesian method to estimate the leeway to reopen, or alternatively the strength of change required to re-establish COVID-19 control, in a range of jurisdictions experiencing different COVID-19 epidemics. We estimated the timing and strength of initial control measures such as widespread distancing and compared the leeway jurisdictions had to reopen immediately after NPI measures to later estimates of leeway. Finally, we quantified risks associated with reopening and the likely burden of new cases due to introductions from other jurisdictions. We found widely varying leeway to reopen. After initial NPI measures took effect, some jurisdictions had substantial leeway (e.g., Japan, New Zealand, Germany) with > 0.99 probability that contact rates were below 80% of the threshold for epidemic growth. Others had little leeway (e.g., the United Kingdom, Washington State) and some had none (e.g., Sweden, California). For most such regions, increases in contact rate of 1.5–2 fold would have had high (> 0.7) probability of exceeding past peak sizes. Most jurisdictions experienced June–August trajectories consistent with our projections of contact rate increases of 1–2-fold. Under such relaxation scenarios for some regions, we projected up to [Formula: see text] 100 additional cases if just one case were imported per week over six weeks, even between jurisdictions with comparable COVID-19 risk. We provide an R package covidseir to enable jurisdictions to estimate leeway and forecast cases under different future contact patterns. Estimates of leeway can establish a quantitative basis for decisions about reopening. We recommend a cautious approach to reopening economies and borders, coupled with strong monitoring for changes in transmission.
format Online
Article
Text
id pubmed-7970422
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-79704222021-03-18 How much leeway is there to relax COVID-19 control measures? Anderson, Sean C. Mulberry, Nicola Edwards, Andrew M. Stockdale, Jessica E. Iyaniwura, Sarafa A. Falcao, Rebeca C. Otterstatter, Michael C. Janjua, Naveed Z. Coombs, Daniel Colijn, Caroline Epidemics Article Following successful non-pharmaceutical interventions (NPI) aiming to control COVID-19, many jurisdictions reopened their economies and borders. As little immunity had developed in most populations, re-establishing higher contact carried substantial risks, and therefore many locations began to see resurgence in COVID-19 cases. We present a Bayesian method to estimate the leeway to reopen, or alternatively the strength of change required to re-establish COVID-19 control, in a range of jurisdictions experiencing different COVID-19 epidemics. We estimated the timing and strength of initial control measures such as widespread distancing and compared the leeway jurisdictions had to reopen immediately after NPI measures to later estimates of leeway. Finally, we quantified risks associated with reopening and the likely burden of new cases due to introductions from other jurisdictions. We found widely varying leeway to reopen. After initial NPI measures took effect, some jurisdictions had substantial leeway (e.g., Japan, New Zealand, Germany) with > 0.99 probability that contact rates were below 80% of the threshold for epidemic growth. Others had little leeway (e.g., the United Kingdom, Washington State) and some had none (e.g., Sweden, California). For most such regions, increases in contact rate of 1.5–2 fold would have had high (> 0.7) probability of exceeding past peak sizes. Most jurisdictions experienced June–August trajectories consistent with our projections of contact rate increases of 1–2-fold. Under such relaxation scenarios for some regions, we projected up to [Formula: see text] 100 additional cases if just one case were imported per week over six weeks, even between jurisdictions with comparable COVID-19 risk. We provide an R package covidseir to enable jurisdictions to estimate leeway and forecast cases under different future contact patterns. Estimates of leeway can establish a quantitative basis for decisions about reopening. We recommend a cautious approach to reopening economies and borders, coupled with strong monitoring for changes in transmission. Published by Elsevier B.V. 2021-06 2021-03-18 /pmc/articles/PMC7970422/ /pubmed/33971429 http://dx.doi.org/10.1016/j.epidem.2021.100453 Text en Crown Copyright © 2021 Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Anderson, Sean C.
Mulberry, Nicola
Edwards, Andrew M.
Stockdale, Jessica E.
Iyaniwura, Sarafa A.
Falcao, Rebeca C.
Otterstatter, Michael C.
Janjua, Naveed Z.
Coombs, Daniel
Colijn, Caroline
How much leeway is there to relax COVID-19 control measures?
title How much leeway is there to relax COVID-19 control measures?
title_full How much leeway is there to relax COVID-19 control measures?
title_fullStr How much leeway is there to relax COVID-19 control measures?
title_full_unstemmed How much leeway is there to relax COVID-19 control measures?
title_short How much leeway is there to relax COVID-19 control measures?
title_sort how much leeway is there to relax covid-19 control measures?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970422/
https://www.ncbi.nlm.nih.gov/pubmed/33971429
http://dx.doi.org/10.1016/j.epidem.2021.100453
work_keys_str_mv AT andersonseanc howmuchleewayistheretorelaxcovid19controlmeasures
AT mulberrynicola howmuchleewayistheretorelaxcovid19controlmeasures
AT edwardsandrewm howmuchleewayistheretorelaxcovid19controlmeasures
AT stockdalejessicae howmuchleewayistheretorelaxcovid19controlmeasures
AT iyaniwurasarafaa howmuchleewayistheretorelaxcovid19controlmeasures
AT falcaorebecac howmuchleewayistheretorelaxcovid19controlmeasures
AT otterstattermichaelc howmuchleewayistheretorelaxcovid19controlmeasures
AT janjuanaveedz howmuchleewayistheretorelaxcovid19controlmeasures
AT coombsdaniel howmuchleewayistheretorelaxcovid19controlmeasures
AT colijncaroline howmuchleewayistheretorelaxcovid19controlmeasures